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INTRODUCTION
Tricuspid valve disease can either be stenotic or regurgitant.While stenotic lesions are very rare and
mainly caused by rheumatic fever or carcinoid disease, the most common disease of the tricuspid
valve is regurgitation (1). As with all valves, primary and secondary entities exist. This opinion
paper will focus on the most frequent pathology, the functional tricuspid regurgitation (FTR),
which primarily is considered as disease of the right ventricle.
WHY DO WE TALK ABOUT THE FORGOTTEN VALVE?
Most editorials on the tricuspid valve speak about “the forgotten or untreated valve.” Why is that
so?
In our view, four facts are responsible for this development:
1. In the early seventies right sided endocarditis due to intravenous drug abuse was treated simply
by surgically removing the valve, leaving behind torrential tricuspid regurgitation (TR). This
was supported surprisingly well. Long-term data was of course scarce due to this selected patient
population.
2. Initially it was believed that left-sided valve surgery would resolve the problem of the tricuspid
valve. TR was generally thought to be a bystander with the main focus on the correction of left
sided pathology. However it has been shown that TR does not resolve following left-sided heart
surgery with relevant influence on long-term survival.
3. For a long time the focus was put on TR alone. Data has shown that not only the presence of TR
represents a significant risk factor for severe TR during follow-up after mitral valve surgery, but
that annular dilatation alone is a predictive factor for later TR.
4. In the pioneering days of heart surgery it was all about survival and TR was never demonstrated
to adversely influence early outcome. This observation applied for the whole complex of right
sided pathologies which only become relevant as patients’ survival of left sided heart disease has
considerably improved. A similar development can be seen in patients suffering from chronic
pulmonary embolic disease. Right heart disease is just not as “appealing” as left heart disease.
WHAT DO THE GUIDELINES TELL US?
Guidelines supported this scientific and practical deficit on therapy for several decades. While
American and European guidelines where relatively fast in listing a class I indication to perform
tricuspid valve repair for severe TR in patients who are undergoing mitral valve (MV) surgery
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both guidelines where for a long period quite silent about
performing concomitant tricuspid valve surgery for coronary
bypass, aortic valve replacement or other cardiac surgery (2, 3).
The ESC Guidelines also listed tricuspid surgery as a Class I
indication in the case of severe primary TR (or tricuspid stenosis)
with symptoms and without severe RV dysfunction (3). The
US guidelines on the other hand only listed this scenario as
“reasonable” and as class IIa indication (2). This is one of the rare
exceptions where valve disease with symptoms is not listed as a
Class I indication for surgery in the guidelines (2) and reflects the
general reluctance to operate on some of these patients who have
already developed irreversible right ventricular (RV) dysfunction.
Patients with FTR remain asymptomatic for a long time
despite considerably impaired right ventricular function (4). As
a result the population with a potential indication to treat TR
is of advanced age, has often already had cardiac surgery and
suffers from extensive RV dysfunction. This is actually a shame as
surgery performed in early stages of the disease is relatively easy
and a straight forward procedure with very acceptable operative
risk (5).
FORGOTTEN OR JUST UNNOTICED?
Despite talk of the “forgotten valve,” already 20 years ago,
renowned specialists in the field had the following messages
which went unnoticed (5, 6):
• Tricuspid annular dilatation is more reliable than
regurgitation and represents a more consistent landmark.
• TR alone is a unreliable parameter as it very much depends on
several factors like volume status, preload, afterload and right
ventricular dysfunction.
• TR is a continuing process, worsening despite treatment of
left-sided pathologies. Already then the group around Gilles
Dreyfus were able to show progression of the disease in 30% of
patients during a follow-up between 5 and 15 years.
Treating annular dilatation beyond a given size improves
functional status and there is a clear trend toward better survival
compared to patients who did not receive treatment.
This concept is supported by several groups including the
American College of Cardiology/American Heart Association
guidelines who included a type IIa recommendation for patients
with a threshold diameter of 40mm (7–13).
The need of treatment of this polymorbid patient population
has resulted in the development of a variety of interventional
devices. But, it becomes evident that while we are again able to
quite effectively treat left sided pathologies with TAVI and mitral
devices, right-sided therapy options still stay far behind.
In the current ESC/ECTS guidelines with updated indications
for the evaluation and surgical intervention in patients with
TR, interventional strategies have only found their place in the
chapter “Gaps in evidence”: “The potential role of transcatheter
tricuspid valve treatment in high-risk patients needs to be
determined (14).”
Sadly, the updated guidelines don’t consider the tricuspid
valve regurgitation as a general consequence of left sided heart
disease but again have the tendency to stress the importance of
the awareness of tricuspid disease in patients with significant
mitral valve disease following data acquired after mitral clip
therapy. In contrast, recent literature demonstrates that even
after TAVI tricuspid valve dysfunction is associated with
significantly increased mortality. This underlines that left-sided
heart disease in general is responsible for FTR (15).
PATHOPHYSIOLOGIC BACKGROUND
From a morphological standpoint FTR is known for its dynamic
disease progression and can be divided into three phases (16):
1. Dilatation of the RV results in dilatation of the tricuspid
annulus. At this stage TRmight not even be present depending
on the degree of annular dilatation and lack of leaflet
coaptation.
2. Progressive dilatation of the RV and tricuspid annulus will
lead to severe lack of coaptation resulting in significant TR.
3. RV dilatation especially in the region of the free wall will in
addition to annular dilatation lead to tethering of the tricuspid
leaflets, due to the attachment of the papillary muscles of the
tricuspid leaflets to the free wall of the RV. A tethering height
of more than 8mm is reported to be predictive of more than
moderate functional TR.
SURGICAL APPROACHES
According to these three phases, surgical repair of the tricuspid
valve for functional TR requires tailored strategies.
In the first two stages, tricuspid annuloplasty alone gives
excellent results. The third phase however necessitates treatment
of the annular dilatation as well as the leaflet tethering since
annuloplasty alone is unlikely to be successful in treating TR.
Here two options come into play—a reconstructive approach or
the replacement of the valve.
A variety of supplemental techniques for addressing leaflet
tethering, such as anterior leaflet patch augmentation, double-
orifice valve or bicuspidization repair, have demonstrated
efficient and lasting results. Not least, these techniques provide
the concept and justification for many proposed catheter-
interventional approaches. Regarding the replacement of the
valve, a potential recurrence of TR due to disease progression
is prevented (16). However, life-long and rather aggressive
anticoagulation therapy after mechanical valve implantation
or the inevitable long-term valve degeneration following
implantation of a biological prosthesis present significant
drawbacks. With the arrival of interventional valve-in-valve
technology, the choice for a biological prosthesis appears to be
preferable.
INTERVENTIONAL APPROACHES
Transcatheter tricuspid valve intervention (TTVI) is at an early
stage of introduction into practice and only a few hundred
patients have been treated so far (17, 18). The first interventional
valve replacement was very recently performed (19).
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According to their mode of action tricuspid valve catheter
devices can be divided into four groups (20):
• Tricuspid valve annuloplasty devices
• Tricuspid edge-to-edge technique
• Heterotopic caval valve devices
• Coaptation devices
Due to the nature of the disease progression, the majority
of patients qualifying for interventional treatment are usually
those with advanced disease (phase two to three). According to
extensive research done on surgically treated patients, most of the
above mentioned interventional devices will not be effective in
treating the pathology. It is our strong opinion, that industry and
doctors should concentrate on annuloplasty devices and devices
replacing the tricuspid valve. It would be unwise to flood the
market with devices not able to treat themost common pathology
and by that depriving very sick patients from an effective
therapy.
CONCLUSION
In conclusion, there is a clearly unmet need for the interventional
treatment of TR mainly in very sick patients with FTR.
Nonetheless device development and introduction must focus
more on the mechanism of the disease in order to effectively
treat it. The focus needs to be on annuloplasty devices and
complete valve replacement strategies. One can only hope, that
the current interest into interventional therapy of the tricuspid
valve disease will bring back the “forgotten valve” into the
conscience of the cardiological and surgical community. On the
one hand, reminding cardiologists, that beside asymptomatic
presentation of their patients a timely referral is mandatory
for allowing a low-risk and optimal surgical intervention,
on the other hand, reminding surgeons to address more
consequently concomitant tricuspid valve disease and to apply
repair strategies. The availability of interventional catheter-
based techniques must not serve as an excuse for again
“forgetting” the dysfunctional tricuspid valve and delaying
therapy.
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